SynerFuse®, Inc., a Minnesota-based medical device company, today announced the appointment of Adeel Khan, M.D., as vice president of regenerative medicine.
“We are pleased to be able to bring Dr. Adeel Khan into our leadership team. He brings a strong blend of clinical, scientific, and strategic insight to SynerFuse® that will help us in our mission to provide relief to people afflicted with chronic low back and leg pain,” said SynerFuse® CEO and Founder Justin Zenanko.
“I am honored to serve as vice president of regenerative medicine at Synerfuse®,” said Khan. This position enables me to concentrate on driving clinically informed innovation that delivers tangible improvements in patient outcomes while supporting the thoughtful adoption of new technologies. SynerFuse® is taking an integrated approach that could reshape how clinicians manage one of the most common and debilitating conditions in healthcare.”
“At SynerFuse®, we believe that individuals with chronic low back and leg pain deserve better outcomes and improved lives,” said Zenanko. “Even when spinal fusion is successful, it can often result in residual chronic neuropathic pain and use of addictive opioids. Today, all patients are prescribed opioids post spinal fusion due to it being an invasive surgery. We are working to create a non-opioid solution for chronic low back and leg pain with our patented therapy, Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™), which integrates spinal fusion hardware and direct nerve stimulation that allows Ultra-Low-Energy™ (ULE™) therapy.”
Dr. Khan is a physician, regenerative medicine expert, and strategic advisor with experience spanning pain, orthopedics, and advanced therapeutic innovation. He was among the first in Canada to publish on intraosseous PRP and has served as a co-investigator in a Health Canada-approved clinical trial for osteoarthritis. His work has been presented at ISSCR and WAPMU, among numerous other international conferences. He brings a strong set of capabilities, knowledge, and experience to companies developing next-generation medical-device and neuromodulation technologies. Meet the team here.